Form 4 for KAPA Kairos Pharma, LTD.
Accepted 2025-12-30 00:00:00 ET · period of report 2025-10-08 · accession 0001493152-25-029601 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-30 | 2025-10-08 | KAPA | Bhowmick Neil | CSO | A - Grant | $0.00 | +171.8K | 1.31M | +15% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | COMMON STOCK | 2025-10-08 | A | A | 171,756 | $0.00 | 1,311,739 | D | — | — | (F1) Represents 171,756 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 171,756 RSUs are scheduled to vest on the on the first anniversary of the grant date which is October 8, 2026. (F2) Consists of (1) 1,135,317 shares of common stock and (2) 176,422 RSUs which remain subject to vesting. |